SSR Mining

SSRM · NASDAQ

$31.27−$0.22 (−0.70%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $31.49

SSRM analyst rating

BuyConsensus of 4 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy4
Hold0
Underperform0
Sell0

12-month price target · 7 analysts

Average $43.49 (+39.1% upside)

Low: $40.61
Now: $31.27
High: $50.40

Upgrades and downgrades

The latest rating actions, newest first

SSRM analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
UBS	Oct 14, 2026	Maintains	Buy	$41.00 → $39.00	78%
CIBC	Oct 5, 2026	Maintains	Outperformer	$48.00 → $50.00	88%
RBC Capital	Sep 16, 2026	Maintains	Outperform	$39.00 → $43.00	49%
RBC Capital	Jul 9, 2026	Maintains	Outperform	$40.00 → $39.00	49%
B of A Securities	Jul 9, 2026	Maintains	Buy	$41.00 → $40.00	60%
UBS	Jul 1, 2026	Maintains	Buy	$40.00 → $39.00	78%
UBS	Jun 30, 2026	Maintains	Buy	$43.00 → $40.00	78%
RBC Capital	Jun 3, 2026	Upgrade	Sector Perform → Outperform	$45.00 → $40.00	49%
UBS	May 6, 2026	Maintains	Buy	$43.00 → $44.00	78%
UBS	Mar 27, 2026	Maintains	Buy	$41.00 → $42.00	78%

The case for and against

Updated Oct 16, 2026

Bull case

SSR Mining is benefiting from a decisive portfolio shift that removes Türkiye operating exposure and concentrates value in North America, with Canada and the US projected to represent 88% of NAV and 79% of EBITDA after the announced transactions. The completed Çöpler sale delivered approximately $1.49 billion in cash, strengthening the balance sheet and creating flexibility for reinvestment, capital returns, and accretive growth initiatives, while the Hod Maden deal should preserve upside through a 4.0% NSR without development capex or permitting risk. With revenue nearly all precious metals—about 80% gold and 18% silver—and shares trading at roughly 0.12x P/NAV relative to peers, the company appears positioned for a higher-quality valuation profile as uncertainty falls.

Bear case

SSR Mining is viewed negatively because, despite elevated free cash flow and a large pro forma net cash position, the stock still trades at a discount to peers, suggesting the market is pricing in meaningful operational and strategic risks. Its earnings power is highly concentrated, with Marigold and CC&V representing about 70% of production, so any underperformance at those assets could disproportionately weaken results. In addition, the company faces cost inflation risk at roughly $2,250/oz AISC and unresolved Copler transaction risk, which could leave it exposed to Turkey and narrower financial flexibility.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.